Aliases & Classifications for Paraplegia

MalaCards integrated aliases for Paraplegia:

Name: Paraplegia 12 76 53 44 15 73
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 53
Paraplegia, Lower 12

Classifications:



External Ids:

Disease Ontology 12 DOID:607
ICD10 33 G82.2 G82.20
ICD9CM 35 344.1
MeSH 44 D010264
NCIt 50 C50687
SNOMED-CT 68 155031004 60389000
UMLS 73 C0030486

Summaries for Paraplegia

MalaCards based summary : Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 49, autosomal recessive and spastic paraplegia 11, autosomal recessive, and has symptoms including hemiplegia, ophthalmoplegia and paraparesis. An important gene associated with Paraplegia is SPG11 (SPG11, Spatacsin Vesicle Trafficking Associated), and among its related pathways/superpathways is Endocytosis. The drugs Acetazolamide and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Paraplegia is an impairment in motor or sensory function of the lower extremities. The word comes from... more...

Related Diseases for Paraplegia

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 490)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 49, autosomal recessive 34.4 SPG11 SPG7 ZFYVE26
2 spastic paraplegia 11, autosomal recessive 34.3 SPG11 SPG21 SPG7
3 spastic paraplegia 15, autosomal recessive 34.0 SPG11 SPG21 SPG7 ZFYVE26
4 spastic paraplegia 20, autosomal recessive 34.0 SPART SPG7
5 spastic paraplegia 24, autosomal recessive 33.8 CYP7B1 SPG21 SPG7
6 mast syndrome 33.8 SPG11 SPG21
7 spastic paraplegia 32, autosomal recessive 33.7 ATL1 SPG11 SPG21 SPG7
8 spastic paraplegia 61, autosomal recessive 33.6 ATL1 REEP1 RTN2 SPAST
9 spastic paraplegia 39, autosomal recessive 33.4 ERLIN2 REEP1 WASHC5 ZFYVE26
10 spastic paraplegia 47, autosomal recessive 33.3 ERLIN2 REEP1 WASHC5
11 spastic paraplegia 35, autosomal recessive 33.3 ERLIN2 SPG11 SPG21 ZFYVE26
12 spastic paraplegia 28, autosomal recessive 33.3 DDHD1 RTN2
13 spastic paraplegia 48, autosomal recessive 33.3 ERLIN2 SPG11 SPG21 ZFYVE26
14 spastic paraplegia 44, autosomal recessive 33.2 ERLIN2 SPG21 ZFYVE27
15 spastic paraplegia 52, autosomal recessive 33.2 DDHD1 RTN2
16 spastic paraplegia 54, autosomal recessive 33.2 DDHD1 RTN2
17 spastic paraplegia 31, autosomal dominant 33.1 ATL1 REEP1 RTN2 SPAST ZFYVE27
18 spastic paraplegia 13, autosomal dominant 32.9 ATL1 ERLIN2 HSPD1 SPAST WASHC5
19 spastic paraplegia 30, autosomal recessive 32.9 ERLIN2 KIF1A REEP1 SPG21 WASHC5
20 spastic paraplegia 10, autosomal dominant 32.8 ATL1 KIF5A REEP1 RTN2 SPG11 ZFYVE27
21 spastic paraplegia 18, autosomal recessive 32.8 ERLIN2 NIPA1 REEP1 SPG21 WASHC5
22 spastic paraplegia 3, autosomal dominant 32.8 ATL1 NIPA1 REEP1 RTN2 SPAST SPG11
23 spastic paraplegia 42, autosomal dominant 32.7 ERLIN2 NIPA1 REEP1 SLC33A1 WASHC5
24 spastic paraplegia 8, autosomal dominant 32.7 ATL1 ERLIN2 NIPA1 REEP1 SPG11 WASHC5
25 masa syndrome 32.7 ATL1 REEP1 SPART SPAST SPG11
26 spastic paraplegia 2, x-linked 32.3 ATL1 ERLIN2 PLP1 REEP1 RTN2 ZFYVE27
27 spastic paraplegia 6, autosomal dominant 32.3 ATL1 ERLIN2 KIF5A NIPA1 REEP1 SLC33A1
28 spasticity 32.2 DDHD1 KIF1A SPG7 WASHC5
29 spastic paraplegia 33, autosomal dominant 32.2 REEP1 RTN2 SPART SPAST ZFYVE27
30 spastic paraplegia 12, autosomal dominant 31.9 ATL1 ERLIN2 KIF5A REEP1 RTN2 SPAST
31 leukodystrophy, hypomyelinating, 4 31.3 HSPD1 PLP1
32 spastic paraplegia 4, autosomal dominant 30.8 ATL1 ERLIN2 NIPA1 REEP1 RTN2 SLC33A1
33 spastic paraparesis 29.8 DDHD1 SPAST SPG11 SPG7
34 hereditary spastic paraplegia 25.7 ATL1 CYP7B1 DDHD1 ERLIN2 HSPD1 KIF1A
35 spastic paraplegia 7, autosomal recessive 12.4
36 spastic paraplegia 17, autosomal dominant 12.4
37 spastic paraplegia, optic atrophy, and neuropathy 12.3
38 spastic paraplegia 56, autosomal recessive 12.3
39 spastic paraplegia 26, autosomal recessive 12.3
40 spastic paraplegia 23 12.3
41 spastic paraplegia 11 12.3
42 spastic paraplegia 72, autosomal recessive 12.3
43 spastic paraplegia 4 12.2
44 spastic paraplegia 5a, autosomal recessive 12.2
45 spastic paraplegia 15 12.2
46 spastic paraplegia 5a 12.2
47 spastic paraplegia 46, autosomal recessive 12.2
48 spastic paraplegia 43, autosomal recessive 12.2
49 spastic paraplegia 45, autosomal recessive 12.2
50 spastic paraplegia 8 12.2

Comorbidity relations with Paraplegia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Multiple Sclerosis
Neurogenic Bladder Osteoporosis
Paralytic Ileus Prostate Cancer
Protein-Energy Malnutrition Spinal Cord Disease
Vascular Myelopathy

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to Paraplegia

Symptoms & Phenotypes for Paraplegia

UMLS symptoms related to Paraplegia:


hemiplegia, ophthalmoplegia, paraparesis, paraplegia, ataxic, monoparesis, paraplegia, cerebral, paraplegia, spinal, monoplegia of lower limb affecting unspecified side, paraplegia, flaccid

GenomeRNAi Phenotypes related to Paraplegia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.98 RTN2
2 Decreased viability GR00402-S-2 9.98 NIPA1 PLP1 REEP1 RTN2 SLC33A1 SPART
3 no effect GR00402-S-1 9.62 PLP1 REEP1 RTN2 SLC33A1 SPART SPAST

MGI Mouse Phenotypes related to Paraplegia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 SPG11 SPG7 ZFYVE26 ATL1 HSPD1 KIF1A
2 nervous system MP:0003631 9.32 SPG11 SPG7 ZFYVE26 HSPD1 KIF1A KIF5A

Drugs & Therapeutics for Paraplegia

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Amphotericin B Approved, Investigational Phase 4,Phase 2 1397-89-3 14956 5280965
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
4 diuretics Phase 4
5 Natriuretic Agents Phase 4
6 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
7 Anticonvulsants Phase 4
8 Anti-Infective Agents Phase 4,Phase 2,Phase 3
9 Antifungal Agents Phase 4,Phase 2
10 Antiparasitic Agents Phase 4,Phase 2
11 Antiprotozoal Agents Phase 4,Phase 2
12 Liposomal amphotericin B Phase 4,Phase 2
13 Carbonic Anhydrase Inhibitors Phase 4
14
Minocycline Approved, Investigational Phase 2, Phase 3 10118-90-8 5281021
15
Acetylcholine Approved Phase 2, Phase 3 51-84-3 187
16
Fenofibrate Approved Phase 2, Phase 3 49562-28-9 3339
17 Cortivazol Investigational Phase 3 1110-40-3
18 Hemostatics Phase 2, Phase 3
19 Anti-Inflammatory Agents Phase 3,Phase 2
20 Fibrin Tissue Adhesive Phase 2, Phase 3,Phase 1
21 Cholinergic Agents Phase 2, Phase 3
22 Neurotransmitter Agents Phase 2, Phase 3,Phase 1,Not Applicable
23 Hypolipidemic Agents Phase 2, Phase 3
24 Lipid Regulating Agents Phase 2, Phase 3
25 Antimetabolites Phase 2, Phase 3
26 Botulinum Toxins Phase 2, Phase 3
27
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
28
Dopamine Approved Phase 1, Phase 2 51-61-6, 62-31-7 681
29
Carbidopa Approved Phase 1, Phase 2 28860-95-9 34359 38101
30
Buspirone Approved, Investigational Phase 1, Phase 2 36505-84-7 2477
31
Levodopa Approved Phase 1, Phase 2 59-92-7 6047
32
Resveratrol Approved, Experimental, Investigational Phase 2 501-36-0 445154
33
Fluconazole Approved, Investigational Phase 2 86386-73-4 3365
34
Tamoxifen Approved Phase 2 10540-29-1 2733526
35
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
36 Protamines Phase 2
37 Atorvastatin Calcium Phase 2 134523-03-8
38 Analgesics Phase 2
39 Cathartics Phase 2
40 abobotulinumtoxinA Phase 2
41 Central Nervous System Depressants Phase 1, Phase 2,Not Applicable
42 Serotonin Agents Phase 1, Phase 2
43 Gastrointestinal Agents Phase 2
44 Neuromuscular Agents Phase 2
45 Hemagglutinins Phase 2
46 Analgesics, Non-Narcotic Phase 2
47 Hormone Antagonists Phase 2
48 Tranquilizing Agents Phase 1, Phase 2
49 onabotulinumtoxinA Phase 2
50 Hormones Phase 2

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery Unknown status NCT01889498 Phase 4 Acetazolamide
2 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
3 Long-term Benefit of Aortic Stent-graft in Patients With Distal Aortic Dissection Terminated NCT01354119 Phase 4
4 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
5 Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica Unknown status NCT02151045 Phase 3
6 Retraining Walking After Spinal Cord Injury Unknown status NCT00059553 Phase 2, Phase 3
7 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
8 Fenofibrate Treatment in SCI Active, not recruiting NCT02455336 Phase 2, Phase 3 Fenofibrate
9 Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord Injury Withdrawn NCT01569360 Phase 3
10 Cethrin in Acute Cervical Spinal Cord Injury Withdrawn NCT02053883 Phase 2, Phase 3 Cethrin (BA-210);Placebo
11 Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System Unknown status NCT01348828 Phase 2
12 Safety and Effectiveness Trial of the Ventana Fenestrated Stent Graft System Unknown status NCT01491945 Phase 2
13 Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest Unknown status NCT02542306 Phase 2 fibrinogen concentrate
14 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Completed NCT02314208 Phase 2 Xenbilox;Tahor
15 Spinal Cord Injury Leg Rehabilitation Completed NCT01498991 Phase 1, Phase 2
16 Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy Completed NCT02188277 Phase 2 Xeomin;Botox®
17 Evaluation of the Vascutek Hybrid Graft for Use in the Replacement of the Aortic Arch and Concomitant Treatment of an Aneurysm/Dissection of the Descending Aorta in the Frozen Elephant Trunk Procedure Completed NCT01541410 Phase 1, Phase 2
18 The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI) Completed NCT01349478 Phase 1, Phase 2
19 Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury Completed NCT01484184 Phase 1, Phase 2 SPINALON (buspirone + levodopa + cardidopa)
20 A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries Completed NCT00500812 Phase 1, Phase 2 Cethrin
21 Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair Completed NCT01920594 Phase 2 GSK1278863;Placebo
22 Treatment With Tamoxifen in Cryptococcal Meningitis Recruiting NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
23 Clinical Outcomes and Radiation Safety After Endovascular Repair of Complex Abdominal Aortic Aneurysms Using CMDs Recruiting NCT02266719 Phase 2
24 Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury Active, not recruiting NCT02326662 Phase 1, Phase 2
25 Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury Not yet recruiting NCT02574585 Phase 2
26 Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries Suspended NCT00073853 Phase 2
27 Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue. Terminated NCT00429013 Phase 2
28 Pilot Study of the Endologix Fenestrated Stent Graft System Unknown status NCT01437215 Phase 1
29 Orthostatic Tolerance During FES (Functional Electrical Stimulation)-Walking in Paraplegia Completed NCT00108043 Phase 1
30 Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI Completed NCT01739023 Phase 1
31 Use of Interactive Gaming for Enhanced Function After Spinal Cord Injury Completed NCT01537978 Phase 1
32 Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia Completed NCT01909154 Phase 1
33 The Safety of ahSC in Chronic SCI With Rehabilitation Recruiting NCT02354625 Phase 1
34 Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection Recruiting NCT03001739 Phase 1 Urapidil Hydrochloride Injection
35 Improving Ambulatory Community Access After Paralysis Recruiting NCT01570816 Phase 1
36 The ReWalk Exoskeletal Walking System for Persons With Paraplegia Unknown status NCT01454570
37 Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia. Unknown status NCT02042508 Not Applicable
38 SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias Unknown status NCT00140829
39 Reciprocating Gait Orthoses for Paraplegia Patients Unknown status NCT02227407 Not Applicable
40 Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During Propulsion Unknown status NCT00785278
41 Home/Work, Community Mobility Skills in the ReWalk Exoskeleton in Persons With SCI Unknown status NCT02118194
42 Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations Unknown status NCT00136630
43 Abdominal Functional Electrical Stimulation in Tetraplegia Unknown status NCT00202631 Not Applicable
44 Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury Unknown status NCT01386762 Early Phase 1
45 Body Composition Assessment in Spinal Cord Injury Unknown status NCT00957762
46 Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis Unknown status NCT02287363
47 Early Intervention to Reduce Bone Loss After Spinal Cord Injury Unknown status NCT02334410 Not Applicable
48 Paraplegic Cycling: Improving Health After Spinal Cord Injury Unknown status NCT00204100 Not Applicable
49 Safety and Tolerance of Local Heat Application in the Paralyzed Area of Patients With Complete Paraplegia Completed NCT03001531 Not Applicable
50 Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis Completed NCT00023075

Search NIH Clinical Center for Paraplegia

Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

Anatomical Context for Paraplegia

MalaCards organs/tissues related to Paraplegia:

41
Spinal Cord, Brain, Bone, Heart, Testes, Bone Marrow, Colon

Publications for Paraplegia

Articles related to Paraplegia:

(show top 50) (show all 1409)
# Title Authors Year
1
Pathogenic Variant of REEP1 in a Korean Family with Autosomal-Dominant Hereditary Spastic Paraplegia. ( 29629531 )
2018
2
A novel heterozygous variant in ERLIN2 causes autosomal dominant pure hereditary spastic paraplegia. ( 29528531 )
2018
3
Resting state fMRI studies in SPG4-linked hereditary spastic paraplegia. ( 29249364 )
2018
4
Targeted next-generation sequencing improves diagnosis of hereditary spastic paraplegia in Chinese patients. ( 29934652 )
2018
5
Quantification of dysarthrI?phonia in a Cypriot family with autosomal recessive hereditary spastic paraplegia associated with a homozygous SPG11 mutation. ( 29804168 )
2018
6
Sacral bone cyst treatment resulting in paraplegia. ( 29351944 )
2018
7
Physical Training and Upper Limb Strength of people with paraplegia: A Systematic Review. ( 29364066 )
2018
8
A hereditary spastic paraplegia-associated atlastin variant exhibits defective allosteric coupling in the catalytic core. ( 29180453 )
2018
9
CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56. ( 29034544 )
2018
10
Reply: POLR3A variants in hereditary spastic paraplegia and ataxia. ( 29236946 )
2018
11
Physical therapists' perceptions about patients with incomplete post-traumatic paraplegia adherence to recommended home exercises: a qualitative study. ( 29914857 )
2018
12
Identification of specific gait patterns in patients with cerebellar ataxia, spastic paraplegia, and Parkinson's disease: A non-hierarchical cluster analysis. ( 28967438 )
2018
13
Audio-visual distraction as an adjunct to standby anaesthesia in persons with paraplegia: a case series of five operations. ( 29423310 )
2018
14
<i>ACO2</i> homozygous missense mutation associated with complicated hereditary spastic paraplegia. ( 29577077 )
2018
15
Hereditary spastic paraplegia. ( 29478605 )
2018
16
Central neuropathic pain in paraplegia alters movement related potentials. ( 29933240 )
2018
17
An unusual case of spinal arteriovenous malformation presenting with severe paraplegia at term pregnancy. ( 29753500 )
2018
18
Radiotherapy for Langerhans cell histiocytosis with paraplegia: A rare oncologic emergency case report in infancy and literature review. ( 29907475 )
2018
19
GPT2 mutations cause developmental encephalopathy with microcephaly and features of complicated hereditary spastic paraplegia. ( 29882329 )
2018
20
Paraplegia following lumbar puncture: a rare complication in spinal dural arteriovenous fistula. ( 29808310 )
2018
21
Anesthetic Considerations for Ivor-Lewis Esophagectomy in a Patient With Hereditary Spastic Paraplegia: A Case Report. ( 29851689 )
2018
22
A Rare Cause of Paraplegia: Myeloid Sarcoma. ( 29393854 )
2018
23
Identification of IFRD1 variant in a Han Chinese family with autosomal dominant hereditary spastic paraplegia associated with peripheral neuropathy and ataxia. ( 29362493 )
2018
24
Sudden paraplegia due to spontaneous bleeding in a thoracic epidural angiolipoma and literature review. ( 29472020 )
2018
25
Novel mutations in the ALDH18A1 gene in complicated hereditary spastic paraplegia with cerebellar ataxia and cognitive impairment. ( 29915212 )
2018
26
Transient paraplegia after neurolytic splanchnic block in a patient with metastatic colon carcinoma. ( 29372026 )
2018
27
Soft tissue sarcoma affecting the right shoulder of a man with paraplegia from a remote traumatic spinal cord injury: a case report. ( 29951280 )
2018
28
A rodent brain-machine interface paradigm to study the impact of paraplegia on BMI performance. ( 29859878 )
2018
29
Pretreatment with diazoxide and erythropoietin: A novel strategy to prevent paraplegia after aortic surgery. ( 29409604 )
2018
30
Compound heterozygous mutations in two different domains of ALDH18A1 do not affect the amino acid levels in a patient with hereditary spastic paraplegia. ( 29754261 )
2018
31
<i>CAPN1</i> mutations broadening the hereditary spastic paraplegia/spinocerebellar ataxia phenotype. ( 29678961 )
2018
32
Subtle Imaging Findings Aid the Diagnosis of Adolescent Hereditary Spastic Paraplegia and Ataxia. ( 29379980 )
2018
33
Clinical phenotype of hereditary spastic paraplegia due to KIF1C gene mutations across life span. ( 29544888 )
2018
34
Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations. ( 29809239 )
2018
35
Prevalence of upper extremity pain in a population of people with paraplegia. ( 29367654 )
2018
36
A case of paraplegia that developed 6A years after thoracic endovascular aortic repair for blunt traumatic aortic injury. ( 29445509 )
2018
37
A novel pathogenic variant of the SPAST gene in a Spanish family with hereditary spastic paraplegia. ( 29526314 )
2018
38
A novel KIAA0196 mutation in a Chinese patient with spastic paraplegia 8: A case report. ( 29768361 )
2018
39
POLR3A variants in hereditary spastic paraplegia and ataxia. ( 29228109 )
2018
40
Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia. ( 29481671 )
2018
41
Clinical and neuroimaging features of autosomal recessive spastic paraplegia 35 (SPG35): case reports, new mutations, and brief literature review. ( 29423566 )
2018
42
Differential changes in the spinal segmental locomotor output in Hereditary Spastic Paraplegia. ( 29353180 )
2018
43
Cardiovascular disease risk marker responses to breaking up prolonged sedentary time in individuals with paraplegia: the Spinal Cord Injury Move More (SCIMM) randomised crossover laboratory trial protocol. ( 29934392 )
2018
44
Voluntary ambulation using voluntary upper limb muscle activity and Hybrid Assistive LimbAr (HALAr) in a patient with complete paraplegia due to chronic spinal cord injury: A case report. ( 29351051 )
2018
45
Effects of Walkbot gait training on kinematics, kinetics, and clinical gait function in paraplegia and quadriplegia. ( 29660947 )
2018
46
Gait phenotypes in paediatric hereditary spastic paraplegia revealed by dynamic time warping analysis and random forests. ( 29518090 )
2018
47
Paraplegia as a presentation of primary hyperoxaluria. ( 29959618 )
2018
48
Dorsal Longitudinal T-Myelotomy (Bischof II Technique): A Useful, Antiquated Procedure for the Treatment of Intractable Spastic Paraplegia. ( 29753900 )
2018
49
Paraplegia Following Spinal Cord Contusion from an Indirect Gunshot Injury. ( 29774197 )
2018
50
A Case of Acute Paraplegia Due to Aortic Dissection in Marfan Syndrome. ( 28479826 )
2017

Variations for Paraplegia

Copy number variations for Paraplegia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 170541 3 155544315 155572167 Copy number SLC33A1 Paraplegias

Expression for Paraplegia

Search GEO for disease gene expression data for Paraplegia.

Pathways for Paraplegia

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 KIF5A SPART SPG21 WASHC5 ZFYVE27

GO Terms for Paraplegia

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.81 ATL1 CYP7B1 ERLIN2 REEP1 RTN2 SLC33A1
2 axon GO:0030424 9.62 ATL1 KIF1A SPG11 ZFYVE27
3 endoplasmic reticulum membrane GO:0005789 9.56 ATL1 CYP7B1 ERLIN2 REEP1 RTN2 SLC33A1
4 midbody GO:0030496 9.54 SPART SPAST ZFYVE26
5 axon cytoplasm GO:1904115 9.43 KIF1A SPAST SPG7
6 endoplasmic reticulum tubular network GO:0071782 8.8 ATL1 REEP1 ZFYVE27

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoskeleton-dependent intracellular transport GO:0030705 9.16 KIF1A KIF5A
2 synaptic vesicle transport GO:0048489 8.96 KIF5A SPG11
3 anterograde axonal transport GO:0008089 8.8 KIF1A SPAST SPG7

Molecular functions related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.26 KIF1A KIF5A REEP1 SPAST
2 ATP-dependent microtubule motor activity, plus-end-directed GO:0008574 9.16 KIF1A KIF5A
3 ATPase activity GO:0016887 8.92 HSPD1 KIF1A KIF5A SPAST

Sources for Paraplegia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....